18F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

Powell Perng; Charles Marcus; Rathan M. Subramaniam

doi:10.2214/AJR.14.13575

¹⁸F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

Powell Perng, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of ¹⁸F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

Original language	English (US)
Pages (from-to)	259-270
Number of pages	12
Journal	American Journal of Roentgenology
Volume	205
Issue number	2
DOIs	https://doi.org/10.2214/AJR.14.13575
State	Published - Aug 1 2015

Keywords

FDG PET/CT
Immune modulation therapy
Melanoma

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.14.13575

Cite this

@article{ecdd861d356744eb8513ad361fd20958,

title = "18F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis",

abstract = "OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.",

keywords = "FDG PET/CT, Immune modulation therapy, Melanoma",

author = "Powell Perng and Charles Marcus and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} American Roentgen Ray Society.",

year = "2015",

month = aug,

day = "1",

doi = "10.2214/AJR.14.13575",

language = "English (US)",

volume = "205",

pages = "259--270",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - 18F-FDG PET/CT and melanoma

T2 - Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

AU - Perng, Powell

AU - Marcus, Charles

AU - Subramaniam, Rathan M.

N1 - Publisher Copyright: © American Roentgen Ray Society.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

AB - OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

KW - FDG PET/CT

KW - Immune modulation therapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84938699299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938699299&partnerID=8YFLogxK

U2 - 10.2214/AJR.14.13575

DO - 10.2214/AJR.14.13575

M3 - Review article

C2 - 26204273

AN - SCOPUS:84938699299

SN - 0361-803X

VL - 205

SP - 259

EP - 270

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -